Actively Recruiting

Phase 3
Age: 12Years - 60Years
All Genders
NCT06294691

Effect of Stem Cell Infusion Time on aGVHD in Patients With Nonmalignant Hematologic Diseases

Led by Anhui Provincial Hospital · Updated on 2025-06-26

198

Participants Needed

6

Research Sites

128 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

To observe the effect of stem cell infusion on the development of acute graft- versus-host disease (aGVHD) in patients with nonmalignant hematologic diseases after allogeneic peripheral blood hematopoietic stem cell transplantation (allo-PBSCT)

CONDITIONS

Official Title

Effect of Stem Cell Infusion Time on aGVHD in Patients With Nonmalignant Hematologic Diseases

Who Can Participate

Age: 12Years - 60Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Definite diagnosis of malignant hematologic disease before transplantation
  • Age between 12 and 60 years old
  • No gender or race restrictions
  • Planned first allogeneic peripheral blood hematopoietic stem cell transplantation (allo-PBSCT)
  • Eastern Cooperative Oncology Group (ECOG) score of 0 to 2
  • No serious organ failure or active infection
  • Willingness to participate in an open randomized controlled study on stem cell infusion timing
  • Signed informed consent form or legal representative consent if patient unable to sign
Not Eligible

You will not qualify if you...

  • Severe organ dysfunction or disease affecting heart, liver, kidneys, or pancreas
  • Pregnancy
  • Refusal to participate in the randomized controlled study on stem cell infusion timing
  • Any life-threatening disease or condition that may compromise safety or study results
  • Drug dependence, uncontrolled psychiatric disorders, or cognitive dysfunction
  • Participation in other clinical studies affecting aGVHD within the past 3 months
  • Anticipated inability to adhere to study procedures due to financial or other issues

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 6 locations

1

The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)

Hefei, Anhui, China, 230036

Actively Recruiting

2

Peking University First Hospital

Beijing, Beijing Municipality, China, 100000

Actively Recruiting

3

The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, China, 450000

Actively Recruiting

4

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China, 430000

Actively Recruiting

5

Rui Jin Hospital Affiliated to Shanghai Jiao Tong University

Shanghai, Shanghai Municipality, China, 200000

Actively Recruiting

6

The First Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, China, 310000

Actively Recruiting

Loading map...

Research Team

X

Xiaoyu Zhu, ph.D

CONTACT

Y

Yue Wu, M.D

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here